Login to Your Account



Pharming Raising EUR25M, Eyeing 2005 Launch Of Lead Product

By Cormac Sheridan


Wednesday, January 21, 2004
Pharming Group NV is raising more than €25 million and converting €5.8 million of debt to equity. The Dutch biotechnology firm, which has struggled financially and emerged from court protection in October 2002, plans to use proceeds for general corporate purposes and to continue development of its lead product, a recombinant form of human C1 inhibitor (rhC1INH). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription